Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer

Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Diaz, Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra D. Eyring, Andrew D. Skora, Brandon S. Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency The New England Journal of Medicine. ,vol. 372, pp. 2509- 2520 ,(2015) , 10.1056/NEJMOA1500596

Nicolas J Llosa, Michael Cruise, Ada Tam, Elizabeth C Wicks, Elizabeth M Hechenbleikner, Janis M Taube, Richard L Blosser, Hongni Fan, Hao Wang, Brandon S Luber, Ming Zhang, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, Cynthia L Sears, Robert A Anders, Drew M Pardoll, Franck Housseau, None, The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints Cancer Discovery. ,vol. 5, pp. 43- 51 ,(2015) , 10.1158/2159-8290.CD-14-0863

Andrew B Sharabi, Michael Lim, Theodore L DeWeese, Charles G Drake, Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy The Lancet Oncology. ,vol. 16, pp. e498- e509 ,(2015) , 10.1016/S1470-2045(15)00007-8

Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled-Filhart, Edward B Garon, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. ,vol. 387, pp. 1540- 1550 ,(2016) , 10.1016/S0140-6736(15)01281-7

Michael B. Bernstein, Sunil Krishnan, James W. Hodge, Joe Y. Chang, Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nature Reviews Clinical Oncology. ,vol. 13, pp. 516- 524 ,(2016) , 10.1038/NRCLINONC.2016.30

Michael Baumann, Mechthild Krause, Jens Overgaard, Jürgen Debus, Søren M. Bentzen, Juliane Daartz, Christian Richter, Daniel Zips, Thomas Bortfeld, Radiation oncology in the era of precision medicine Nature Reviews Cancer. ,vol. 16, pp. 234- 249 ,(2016) , 10.1038/NRC.2016.18

Sandra Demaria, C. Norman Coleman, Silvia C. Formenti, Radiotherapy: Changing the Game in Immunotherapy Trends in cancer. ,vol. 2, pp. 286- 294 ,(2016) , 10.1016/J.TRECAN.2016.05.002

Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares, Lung cancer: current therapies and new targeted treatments The Lancet. ,vol. 389, pp. 299- 311 ,(2017) , 10.1016/S0140-6736(16)30958-8

Josephine Kang, Sandra Demaria, Silvia Formenti, Current clinical trials testing the combination of immunotherapy with radiotherapy Journal for ImmunoTherapy of Cancer. ,vol. 4, pp. 51- 51 ,(2016) , 10.1186/S40425-016-0156-7

Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer, None, Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 375, pp. 1823- 1833 ,(2016) , 10.1056/NEJMOA1606774